规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
25mg |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
在 OCI-AML-3 细胞中,双嘧达莫(5 μM;15 分钟)使细胞内 cAMP 水平增加 2.5 倍 [2]。当他汀类药物和双嘧达莫(5 μM;48 小时)联合使用时,原代 AML 细胞会发生凋亡 [2]。 Dipyridamole(5 μM;48 小时)以不依赖于 cAMP/PKA 的方式抑制他汀类药物诱导的 SREBP2 激活 [2]。
|
---|---|
体内研究 (In Vivo) |
双嘧达莫(10毫克/千克);口服,每天一次,持续十八天)抑制肿瘤生长,增强血流,同时改变肿瘤组织,并增加血小板浸润[3]。
|
细胞实验 |
细胞凋亡分析[2]
细胞类型: AML(OCI-AML-2、OCI-AML-3)细胞系 测试浓度: 5 μM 孵育时间: 48 小时 实验结果:在 OCI-AML-2 和OCI-AML-3 细胞。 RT-PCR[2] 细胞类型: LP1 细胞系 测试浓度: 5 μM 孵育持续时间:16小时 实验结果:增加癌细胞对他汀类药物诱导的细胞凋亡的敏感性。 |
动物实验 |
Animal/Disease Models: C57BL/6-LLC tumor-bearing mouse model [3]
Doses: 10 mg/kg Route of Administration: po (oral gavage); 10 mg/kg; one time/day for 18 days Experimental Results: Reduce tumors in tumor-bearing mice grow. |
参考文献 |
[1]. Kerndt CC, Nagalli S. Dipyridamole. 2021 Nov 25. In: StatPearls . Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32119342.
[2]. Longo, Joseph, etal. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Molecular oncology vol. 14,10 (2020): 2533-2545 [3]. Wang, Jiaan-Der, etal. Exosomal HMGB1 Promoted Cancer Malignancy. Cancers vol. 13,4 877. 19 Feb. 2021. |
分子式 |
C24H40N8O4
|
|
---|---|---|
分子量 |
504.63
|
|
CAS号 |
58-32-2
|
|
相关CAS号 |
Dipyridamole-d20;1189983-52-5;Dipyridamole-d16
|
|
SMILES |
OCCN(CCO)C1=NC(N2CCCCC2)=C(N=C(N(CCO)CCO)N=C3N4CCCCC4)C3=N1
|
|
InChi Key |
IZEKFCXSFNUWAM-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
|
|
化学名 |
2,2,2,2-((4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (4.95 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 2.5 mg/mL (4.95 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.5 mg/mL (4.95 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9816 mL | 9.9082 mL | 19.8165 mL | |
5 mM | 0.3963 mL | 1.9816 mL | 3.9633 mL | |
10 mM | 0.1982 mL | 0.9908 mL | 1.9816 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02121756 | Completed Has Results | Drug: Dipyridamole Drug: Placebo, then Dipyridamole |
HIV Infection | Sharon Riddler | July 2014 | Phase 1 Phase 2 |
NCT04424901 | Terminated Has Results | Drug: Placebo Drug: Dipyridamole Tablets |
COVID-19 Pneumonia Vascular Complications |
UConn Health | May 3, 2020 | Phase 2 |
NCT01613755 | Completed | Drug: Metformin, dipyridamole Drug: Metformin |
Diabetes | Radboud University Medical Center | April 2012 | Phase 4 |
NCT00457405 | Completed | Ischemia-Reperfusion Injury | Radboud University Medical Center | June 2007 | Phase 4 |
Dipyridamole inhibits the sterol‐regulated feedback loop of the MVA pathway. Schematic representation of the MVA pathway. Statins inhibit the rate‐limiting enzyme of the pathway, HMGCR, which catalyzes the conversion of HMG‐CoA to MVA. MVA is subsequently used to synthesize various metabolites that are important for cell growth and survival, including GGPP and cholesterol. Statin‐mediated cholesterol depletion induces the cleavage and activation of SREBP2, which in turn induces the transcription of genes involved in MVA metabolism to restore homeostasis. We previously identified that the drug dipyridamole can inhibit statin‐induced SREBP2 activation; however, the mechanism by which dipyridamole inhibits SREBP2 cleavage remains poorly understood. td> |
Dipyridamole mitigated LLC cell proliferation. td> |
Dipyridamole and GW4869 mitigated tumor growth. LLC cells or saline vehicle were implanted into C57BL/6 mice and allowed to grow for 3 weeks. Three days after implantation, dipyridamole (10 mg/kg) and GW4869 (2.5 mg/kg) were administrated daily up until the end of the experiment. The tumor volume (A), resected tumor tissues (B), and tumor mass (C) are shown. The total white blood cells (WBC) (D), sP-selectin (E), TGF-β1 (F), and platelets (G) in blood samples were determined. * p < 0.05 vs. saline or sham untreated group and # p < 0.05 vs. LLC untreated group, n = 8. td> |